Pharmacogenomics in Dermatology: Tools for Understanding Gene-drug Associations

Overview

Journal Semin Cutan Med Surg

Specialties Dermatology
General Surgery

Date 2019 May 4

PMID 31051019

Citations 3

Authors

Roxana Daneshjou

Rachel Huddart

Teri E Klein

Russ B Altman

Affiliations

Soon will be listed here.

Abstract

Pharmacogenomics aims to associate human genetic variability with differences in drug phenotypes in order to tailor drug treatment to individual patients. The massive amount of genetic data generated from large cohorts of patients with variable drug phenotypes have led to advances in this field. Understanding the application of pharmacogenomics in dermatology could inform clinical practice and provide insight for future research. The Pharmacogenomics Knowledge Base and the Clinical Pharmacogenetics Implementation Consortium are among the resources to help clinicians and researchers navigate the many gene-drug associations that have already been discovered. The implementation of clinical pharmacogenomics within health care systems remains an area of ongoing development. This review provides an introduction to the field of pharmacogenomics and to current pharmacogenomics resources using examples of gene-drug associations relevant to the field of dermatology.

Citing Articles

Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.

Cacabelos R, Naidoo V, Corzo L, Cacabelos N, Carril J Int J Mol Sci. 2021; 22(24).

PMID: 34948113 PMC: 8704264. DOI: 10.3390/ijms222413302.

Clinical Application of Pharmacogenetic Markers in the Treatment of Dermatologic Pathologies.

Membrive Jimenez C, Perez Ramirez C, Martin A, Vieira Maroun S, Arias Santiago S, Ramirez Tortosa M Pharmaceuticals (Basel). 2021; 14(9).

PMID: 34577605 PMC: 8471650. DOI: 10.3390/ph14090905.

The role of pharmacogenetics in keloid scar treatment: A literature review.

Searle T, Ali F, Al-Niaimi F Scars Burn Heal. 2020; 6:2059513120941704.

PMID: 32922964 PMC: 7446553. DOI: 10.1177/2059513120941704.

References

Johnson M, Hageboutros A, Wang K, High L, Smith J, Diasio R . Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res. 1999; 5(8):2006-11. View

Gupta M, Guptat A . The use of antidepressant drugs in dermatology. J Eur Acad Dermatol Venereol. 2002; 15(6):512-8. DOI: 10.1046/j.1468-3083.2001.00278.x. View

Mallal S, Nolan D, Witt C, Masel G, Martin A, Moore C . Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002; 359(9308):727-32. DOI: 10.1016/s0140-6736(02)07873-x. View

Liu V, Mackool B . Mycophenolate in dermatology. J Dermatolog Treat. 2003; 14(4):203-11. DOI: 10.1080/09546630310016826. View

Meyer U . Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat Rev Genet. 2004; 5(9):669-76. DOI: 10.1038/nrg1428. View

Patel A, Swerlick R, McCall C . Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol. 2006; 55(3):369-89. DOI: 10.1016/j.jaad.2005.07.059. View

Madan V, Griffiths C . Systemic ciclosporin and tacrolimus in dermatology. Dermatol Ther. 2007; 20(4):239-50. DOI: 10.1111/j.1529-8019.2007.00137.x. View

Mallal S, Phillips E, Carosi G, Molina J, Workman C, Tomazic J . HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008; 358(6):568-79. DOI: 10.1056/NEJMoa0706135. View

Schackman B, Scott C, Walensky R, Losina E, Freedberg K, Sax P . The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS. 2008; 22(15):2025-33. PMC: 2648845. DOI: 10.1097/QAD.0b013e3283103ce6. View

10.

Woillard J, Rerolle J, Picard N, Rousseau A, Drouet M, Munteanu E . Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele. Br J Clin Pharmacol. 2010; 69(6):675-83. PMC: 2883760. DOI: 10.1111/j.1365-2125.2010.03625.x. View

11.

Relling M, Klein T . CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011; 89(3):464-7. PMC: 3098762. DOI: 10.1038/clpt.2010.279. View

12.

Relling M, Gardner E, Sandborn W, Schmiegelow K, Pui C, Yee S . Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011; 89(3):387-91. PMC: 3098761. DOI: 10.1038/clpt.2010.320. View

13.

Schram M, Borgonjen R, Bik C, van der Schroeff J, van Everdingen J, Spuls P . Off-label use of azathioprine in dermatology: a systematic review. Arch Dermatol. 2011; 147(4):474-88. DOI: 10.1001/archdermatol.2011.79. View

14.

Martin M, Klein T, Dong B, Pirmohamed M, Haas D, Kroetz D . Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther. 2012; 91(4):734-8. PMC: 3374459. DOI: 10.1038/clpt.2011.355. View

15.

Whirl-Carrillo M, McDonagh E, Hebert J, Gong L, Sangkuhl K, Thorn C . Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012; 92(4):414-7. PMC: 3660037. DOI: 10.1038/clpt.2012.96. View

16.

Hershfield M, Callaghan J, Tassaneeyakul W, Mushiroda T, Thorn C, Klein T . Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2012; 93(2):153-8. PMC: 3564416. DOI: 10.1038/clpt.2012.209. View

17.

Karczewski K, Daneshjou R, Altman R . Chapter 7: Pharmacogenomics. PLoS Comput Biol. 2013; 8(12):e1002817. PMC: 3531317. DOI: 10.1371/journal.pcbi.1002817. View

18.

Relling M, Gardner E, Sandborn W, Schmiegelow K, Pui C, Yee S . Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther. 2013; 93(4):324-5. PMC: 3604643. DOI: 10.1038/clpt.2013.4. View

19.

Hicks J, Swen J, Thorn C, Sangkuhl K, Kharasch E, Ellingrod V . Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013; 93(5):402-8. PMC: 3689226. DOI: 10.1038/clpt.2013.2. View

20.

Leckband S, Kelsoe J, Dunnenberger H, George Jr A, Tran E, Berger R . Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther. 2013; 94(3):324-8. PMC: 3748365. DOI: 10.1038/clpt.2013.103. View